Decompensated Cirrhosis, Fecal Microbiota Transplantation
Conditions
Keywords
Cirrhosis, Fecal Microbiota Transplantation, Intestinal flora, Intestinal mucosal barrier, Intestinal Bacteria Flora Disturbance
Brief summary
Imbalance of gut bacteria is suspected to play a key role driving the progression of cirrhosis and there is hope manipulation of these bacteria may be beneficial. This study will determine if fecal microbiota transplantation is an effective and safe treatment for decompensated cirrhosis.
Detailed description
Two groups of inpatients with decompensated cirrhosis will be randomized using random sequence generator into experimental and control groups. Two groups will given traditional treatments and experimental group will added treatment with fecal microbiota transplantation via endoscope and/or cenema.The liver function parameters, adverse events complication, systemic inflammatory markers, Intestinal mucosa structure, permeability changes in the intestinal mucosal barrier, Microbiota composition will be assessed and thereafter at 1 month and 3 months & subjects will be clinically assessed for improvement or worsening.
Interventions
BIOLOGICALFMT
Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1
traditional treatments for Decompensated Cirrhosis in part 2
Sponsors
First Affiliated Hospital of Chengdu Medical College
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. \>18 years of age 2. Agreed to participate in this clinical study and signed informed consent, follow-up time greater than 3 months. 3. Comply with the diagnostic criteria of decompensated liver cirrhosis, including liver function damage, portal hypertension clinical manifestations, laboratory and imaging studies.
Exclusion criteria
1. Ongoing bacterial infection requiring antibiotic treatment. 2. current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening (significant alcohol consumption is defined as more than 20 g/day in females and more than 30 g/day in males, on average). 3. consecutive months within 1 year prior to screening. 4. Treatment with antibiotics or probiotics in the preceding 3 months. 5. Inability to safely perform an GastroIntestinal endoscopy. 6. No history of recent spontaneous bacterial peritonitis or gastrointestinal bleeding.(14 days). 7. Human Immunodeficiency Virus (HIV) infection. 8. Active, serious medical disease with likely life expectancy less than 5 years. 9. Active substance abuse including inhaled or injection drugs in the year prior to screening. 10. pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use effective birth control during the trial, breast feeding. 11. Any other condition which, in the opinion of the investigator, would impede compliance or hinder completion of the study. 12. History of severe (anaphylactic) food allergy. 13. History of gastroparesis or altered gastric motility - 14. Psychiatric disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of adverse events complication rate in all patients in both groups | 3 months | Adverse events like the general situation, defecate situation and possible clinical events, including: Incidence of new onset upper gastrointestinal bleed in both groups; development of new onset of ascites in both groups.; Number of Spontaneous Bacterial peritonitis cases in both groups. Acute on Chronic Liver failure cases in both groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in systemic inflammatory markers like TNF-α in both groups. | 3 months | — |
| Reduction in systemic inflammatory markers like IL-6 in both groups. | 3 months | Improvement is defined as improvement in Intestinal mucosa structure pre and post treatment. |
| Reduction in systemic inflammatory markers like serum endotoxins in both groups. | 3 months | — |
| Improvement in liver function test as compared to baseline in both groups. | 3 months | — |
| Histological changes in the intestinal biopsy in both groups. | 3 months | — |
| Microbiota composition | 3 months | Deep sequencing of the microbiota at baseline and post-FMT. |
| Diamine oxidase（DAO） | 3 months | — |
Countries
China
Contacts
Primary ContactYan Zhou, Ph.D
Outcome results
None listed